Ser425

Site Information
SIRCSsVs_______ SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 448336

In vivo Characterization
Methods used to characterize site in vivo:	mutation of modification site ( 2 ) , phospho-antibody ( 2 ) , western blotting ( 2 )
Relevant cell line - cell type - tissue:	MEF (fibroblast) ( 2 ) , R22 ('muscle, smooth') ( 2 ) , SYF (fibroblast) ( 2 ) , vascular smooth muscle cell ('muscle, smooth') ( 2 )

Upstream Regulation
Treatments:	TGF-beta ( 2 ) , Y27632 ( 2 )

References
1	Kadam AH, et al. (2022) Targeting caveolae to pump bispecific antibody to TGF-β into diseased lungs enables ultra-low dose therapeutic efficacy. PLoS One 17, e0276462 36413536 Curated Info
2	Samarakoon R, Higgins SP, Higgins CE, Higgins PJ (2008) TGF-beta1-induced plasminogen activator inhibitor-1 expression in vascular smooth muscle cells requires pp60(c-src)/EGFR(Y845) and Rho/ROCK signaling. J Mol Cell Cardiol 44, 527-38 18255094 Curated Info